Stock listing
Dusseldorf:AJ8 Agenus Inc. Aktie
German listing (Dusseldorf) of Agenus Inc. · home listing NASDAQ:AGEN
Follow Agenus Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:AGEN
$5.97 USD -0.43 (-6.7%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:AGEN
- Day range
- $5.90 – $6.26 USDNov 20, 2026
- Volume
- 711,696 sharesNov 20, 2026
- Market cap
- $270.1M USDAt the close on Nov 20, 2026 · price × 45.25M shares outstanding
- 52-week range
- $2.71 – $10.31 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $7.02M USDMedian day 782,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:AGEN · Home | $5.97 USD | -0.43 (-6.7%) | 711,696 | $6.00 | $6.26 | $5.90 | $6.40 | Close on Nov 20, 2026 |
| Frankfurt:AJ8 | €5.40 EUR | -0.35 (-6.1%) | — | €5.45 | €5.45 | €5.40 | €5.75 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AGEN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $5.97 | -0.43 | -6.7% | $6.00 | $6.26 | $5.90 | 711,696 | |
| $6.40 | +0.19 | +3.1% | $6.17 | $6.50 | $5.98 | 880,001 | |
| $6.21 | -0.08 | -1.3% | $6.19 | $6.447 | $5.96 | 856,952 | |
| $6.29 | -0.44 | -6.5% | $6.60 | $6.665 | $6.245 | 568,264 | |
| $6.73 | -0.14 | -2.0% | $6.97 | $6.97 | $6.50 | 464,089 | |
| $6.87 | -0.35 | -4.8% | $7.07 | $7.085 | $6.775 | 498,928 | |
| $7.22 | +0.20 | +2.8% | $7.13 | $7.29 | $7.02 | 429,708 | |
| $7.02 | -0.13 | -1.8% | $7.09 | $7.13 | $6.645 | 691,626 | |
| $7.15 | 0.00 | 0.0% | $7.39 | $7.65 | $7.111 | 840,731 | |
| $7.15 | +0.71 | +11.0% | $6.54 | $7.20 | $6.372 | 862,177 | |
| $6.44 | -0.53 | -7.6% | $6.81 | $6.82 | $6.11 | 1,330,816 | |
| $6.97 | +0.30 | +4.5% | $6.99 | $7.06 | $6.85 | 729,893 | |
| $6.67 | +0.14 | +2.1% | $6.59 | $6.835 | $6.50 | 499,019 | |
| $6.53 | -0.31 | -4.5% | $6.85 | $6.855 | $6.43 | 595,081 | |
| $6.84 | -0.25 | -3.5% | $6.91 | $7.09 | $6.69 | 564,302 | |
| $7.09 | -0.04 | -0.6% | $7.13 | $7.30 | $6.942 | 624,978 | |
| $7.13 | +0.48 | +7.2% | $6.51 | $7.14 | $6.47 | 744,010 | |
| $6.65 | +0.49 | +8.0% | $6.13 | $6.67 | $6.11 | 838,971 | |
| $6.16 | -0.17 | -2.7% | $6.49 | $6.49 | $6.14 | 687,566 | |
| $6.33 | -0.18 | -2.8% | $6.50 | $6.50 | $6.16 | 509,035 | |
| $6.51 | +0.11 | +1.7% | $6.32 | $6.52 | $6.236 | 553,901 | |
| $6.40 | -0.02 | -0.3% | $6.459 | $6.54 | $6.31 | 789,524 | |
| $6.42 | +0.24 | +3.9% | $6.10 | $6.58 | $6.05 | 819,337 | |
| $6.18 | +0.14 | +2.3% | $6.13 | $6.30 | $6.055 | 734,858 | |
| $6.04 | -0.64 | -9.6% | $6.65 | $6.70 | $6.00 | 1,028,732 | |
| $6.68 | +0.18 | +2.8% | $6.52 | $6.99 | $6.51 | 815,431 | |
| $6.50 | -0.45 | -6.5% | $6.88 | $7.14 | $6.46 | 980,140 | |
| $6.95 | -0.48 | -6.5% | $7.30 | $7.34 | $6.81 | 991,800 | |
| $7.43 | -0.24 | -3.1% | $7.63 | $7.66 | $7.39 | 572,500 | |
| $7.67 | +0.13 | +1.7% | $7.50 | $7.79 | $7.38 | 710,200 | |
| $7.54 | -0.03 | -0.4% | $7.57 | $7.66 | $7.24 | 1,214,800 | |
| $7.57 | +0.08 | +1.1% | $7.28 | $7.62 | $7.27 | 1,155,100 | |
| $7.49 | -1.24 | -14.2% | $8.49 | $8.49 | $7.47 | 1,522,900 | |
| $8.73 | +0.37 | +4.4% | $8.54 | $8.76 | $8.11 | 956,100 | |
| $8.36 | +0.03 | +0.4% | $8.36 | $8.61 | $8.08 | 1,085,200 | |
| $8.33 | -1.60 | -16.1% | $9.95 | $9.99 | $8.28 | 1,949,200 | |
| $9.93 | +0.04 | +0.4% | $9.92 | $10.31 | $9.62 | 1,366,600 | |
| $9.89 | +0.46 | +4.9% | $9.66 | $10.06 | $9.43 | 1,500,000 | |
| $9.43 | +0.89 | +10.4% | $8.71 | $9.71 | $8.47 | 2,764,000 | |
| $8.54 | +0.04 | +0.5% | $8.57 | $8.68 | $8.40 | 672,400 | |
| $8.50 | +0.10 | +1.2% | $8.32 | $8.60 | $8.20 | 635,700 | |
| $8.40 | -0.30 | -3.4% | $8.70 | $8.70 | $8.39 | 610,000 | |
| $8.70 | +0.37 | +4.4% | $8.26 | $8.82 | $8.16 | 993,300 | |
| $8.33 | +0.48 | +6.1% | $7.80 | $8.60 | $7.60 | 1,299,400 | |
| $7.85 | +0.63 | +8.7% | $7.48 | $7.88 | $7.33 | 2,084,000 | |
| $7.22 | +0.01 | +0.1% | $7.31 | $7.40 | $7.09 | 765,400 | |
| $7.21 | +0.05 | +0.7% | $7.25 | $7.33 | $7.06 | 686,000 | |
| $7.16 | +0.03 | +0.4% | $7.05 | $7.19 | $6.81 | 779,500 | |
| $7.13 | +0.19 | +2.7% | $7.03 | $7.18 | $6.82 | 752,200 | |
| $6.94 | +0.05 | +0.7% | $6.93 | $7.02 | $6.70 | 790,500 | |
| $6.89 | +0.03 | +0.4% | $6.76 | $7.04 | $6.66 | 893,600 | |
| $6.86 | -0.57 | -7.7% | $7.60 | $7.61 | $6.78 | 1,445,700 | |
| $7.43 | -0.81 | -9.8% | $8.14 | $8.18 | $7.42 | 1,207,300 | |
| $8.24 | 0.00 | 0.0% | $8.14 | $8.38 | $7.99 | 986,200 | |
| $8.24 | +0.15 | +1.9% | $8.12 | $8.31 | $7.98 | 738,700 | |
| $8.09 | +0.10 | +1.3% | $8.07 | $8.28 | $7.69 | 663,700 | |
| $7.99 | +0.38 | +5.0% | $7.56 | $8.00 | $7.54 | 676,300 | |
| $7.61 | -0.05 | -0.7% | $7.68 | $7.76 | $7.50 | 719,300 | |
| $7.66 | -0.15 | -1.9% | $7.98 | $8.07 | $7.61 | 741,100 | |
| $7.81 | -0.44 | -5.3% | $8.28 | $8.52 | $7.78 | 782,800 | |
| $8.25 | -0.11 | -1.3% | $8.30 | $8.40 | $8.03 | 776,700 | |
| $8.36 | +0.69 | +9.0% | $7.80 | $8.50 | $7.80 | 1,181,200 | |
| $7.67 | -0.42 | -5.2% | $8.07 | $8.07 | $7.60 | 772,900 | |
| $8.09 | +0.60 | +8.0% | $7.58 | $8.35 | $7.58 | 1,517,300 | |
| $7.49 | -0.77 | -9.3% | $8.22 | $8.25 | $7.31 | 1,575,700 |
Splits
2 splits since 2011 · NASDAQ:AGEN · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation | |
| 1-for-6 | Consolidation |
- Ticker
- Dusseldorf:AJ8
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Dusseldorf
- Currency
- EUR
What changed lately
Latest news release · Nov 6, 2026
Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 33 slides
Latest news
Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026
Nov 6, 2026
Closed $7.15 (+11.0%) on Nov 6, 2026
Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study
Nov 5, 2026
Closed $6.44 (-7.6%) on Nov 5, 2026
Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
Nov 2, 2026
Closed $6.67 (+2.1%) on Nov 3, 2026
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Nov 2, 2026
Closed $6.53 (-4.5%) on Nov 2, 2026
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
Oct 25, 2026
Closed $6.16 (-2.7%) on Oct 26, 2026
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
Oct 22, 2026
Closed $6.33 (-2.8%) on Oct 23, 2026
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference
Oct 9, 2026
Closed $7.67 (+1.7%) on Oct 9, 2026
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
Oct 8, 2026
Closed $7.54 (-0.4%) on Oct 8, 2026
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Oct 3, 2026
Closed $8.73 (+4.4%) on Oct 5, 2026
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
Oct 2, 2026
Closed $8.36 (+0.4%) on Oct 2, 2026
Agenus Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 43 in the last 12 months · 184 in all · newest Nov 6, 2026 · oldest 2019
- Calls
- 19 calls with a replay · 19 with a transcript · latest Aug 27, 2025
- Decks
- 34 decks · latest November 2026
Where Agenus Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:AGEN · Home listing | NASDAQ | United States | USD |
| LS Exchange:A403RK | LS Exchange | Germany | EUR |
| Lang & Schwarz:A403RK | Lang & Schwarz | Germany | EUR |
| gettex:AJ8 | gettex | Germany | EUR |
| BX Swiss:AGEN | BX Swiss | Switzerland | CHF |
| BOATS:AGEN | BOATS | United States | USD |
| Dusseldorf:AJ8 · This page | Dusseldorf | Germany | EUR |
| Frankfurt:AJ8 | Frankfurt | Germany | EUR |
| Munich:AJ8 | Munich | Germany | EUR |
| Tradegate:AJ8 | Tradegate | Germany | EUR |
Valuation
EV/sales 1.6× against a median of 252×: the lowest of 3 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $218.3M USD
- P/E
- 9.2×
- EV/sales
- 1.6×
- EV/EBITDA
- 4.0×
- Price/book
- Negative equity
- Gross margin
- 100.0%
- Operating margin
- 38.9%
- Net margin
- 22.0%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.80
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Agenus Inc. · NASDAQ:AGEN | US$270.1M | US$218.3M | 9.2× | 1.6× | 4.0× | n/a | 22.0% | n/a | 1.80 |
| Fulcrum Therapeutics, Inc. · NASDAQ:FULC | US$281.8M | −US$17.87M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.42 |
| Circio Holding ASA · OSL:CRNA | US$281.1M | US$225.9M | n/a | n/a | n/a | 5.3× | n/a | 0.0× | n/a |
| Relmada Therapeutics, Inc. · NASDAQ:RLMD | US$279.5M | US$77.42M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.57 |
| Benitec Biopharma Inc. · NASDAQ:BNTC | US$276.1M | US$99.78M | n/a | n/a | n/a | 1.6× | n/a | 0.0× | 1.46 |
| Vicore Pharma Holding AB · OMXSTO:VICO | US$271.4M | US$182.7M | n/a | 467× | n/a | 3.3× | n/a | 0.0× | n/a |
| Galectin Therapeutics Inc. · NASDAQ:GALT | US$271.4M | US$293.0M | n/a | n/a | n/a | n/a | n/a | n/a | 1.20 |
| AgomAb Therapeutics NV · NASDAQ:AGMB | US$268.4M | −US$6.88M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.29 |
| Kyverna Therapeutics, Inc. · NASDAQ:KYTX | US$263.5M | US$117.8M | n/a | n/a | n/a | 2.0× | n/a | 0.2× | 2.02 |
| PepGen Inc. · NASDAQ:PEPG | US$261.8M | US$172.6M | n/a | n/a | n/a | 2.5× | n/a | 0.1× | 1.11 |
| Ocugen, Inc. · NASDAQ:OCGN | US$260.6M | US$178.1M | n/a | 37.3× | n/a | n/a | n/a | n/a | 1.47 |
| Median of the others | US$271.4M | US$145.2M | 252× | 1.8× | 0.0× | 1.38 |
Forecasts
3 strong buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 27.00 USD · Analysts' mean
- EPS, year to Dec 2026
- 0.82 · 1 analyst
- Revenue, year to Dec 2026
- 130.7M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Garo H. Armen | Chairman and Chief Executive Officer |
| Jennifer Buell | President and CEO of MiNK Therapeutics and Chairman, Executive Council at Agenus |
| Brian Corvese | President and founder of Vencor Capital |
| Zack Armen | VP, Corporate Development & Investor Relations |
| Craig Winter | Chief Information Officer |
| José Iglesias | Chief Medical Affairs Officer |
| Robin Taylor | Chief Commercial Officer |
| Steven O’Day | Chief Medical Officer |
| Susan Hirsch | Managing Director at Nuveen |
| Tracy Mazza Clemente | Chief People Officer |
Board
| Director | Role |
|---|---|
| Garo H. Armen | Chairman and Chief Executive Officer |
| Jennifer Buell | President and CEO of MiNK Therapeutics and Chairman, Executive Council at Agenus |
| Timothy R. Wright | Lead Director |
| Tom Harrison | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Agenus (NASDAQ:AGEN) Q2 2025 Earnings Call | Wed, Aug 27, 2025 · 9:30 AM ET | Replay |
| Agenus (NASDAQ:AGEN) Q4 2024 Earnings Call | Tue, Mar 11, 2025 · 8:30 AM ET | Replay |
| Agenus (NASDAQ:AGEN) Q3 2024 Earnings Call | Tue, Nov 12, 2024 · 8:30 AM ET | Replay |
| Agenus (NASDAQ:AGEN) Q1 2024 Earnings Call | Tue, May 07, 2024 · 9:30 AM ET | Replay |
| Agenus (NASDAQ:AGEN) Q4 2023 Earnings Call | Thu, Mar 14, 2024 · 8:30 AM ET | Replay |
| Agenus (NASDAQ:AGEN) Q3 2023 Earnings Call | Tue, Nov 07, 2023 · 9:00 AM ET | Replay |
| Agenus (NASDAQ:AGEN) Q1 2023 Earnings Call | Tue, May 09, 2023 · 8:30 AM ET | Replay |
| Agenus (NASDAQ:AGEN) Q4 2022 Earnings Call | Tue, Mar 14, 2023 · 8:30 AM ET | Replay |
| Agenus (NASDAQ:AGEN) Q3 2022 Earnings Call | Tue, Nov 08, 2022 · 8:30 AM ET | Replay |
| Agenus (NASDAQ:AGEN) Q2 2022 Earnings Call | Tue, Aug 09, 2022 · 8:30 AM ET | Replay |
All 19 calls
| Call | When | Status |
|---|---|---|
| Agenus (NASDAQ:AGEN) Q1 2022 Earnings Call | Tue, May 10, 2022 · 8:30 AM ET | Replay |
| Agenus (NASDAQ:AGEN) Q4 2021 Earnings Call | Tue, Mar 01, 2022 · 8:30 AM ET | Replay |
| Agenus (NASDAQ:AGEN) Q3 2021 Earnings Call | Tue, Nov 09, 2021 · 8:30 AM ET | Replay |
| Agenus (NASDAQ:AGEN) Q2 2021 Earnings Call | Mon, Aug 09, 2021 · 8:30 AM ET | Replay |
| Agenus (NASDAQ:AGEN) Q1 2021 Earnings Call | Thu, May 06, 2021 · 8:30 AM ET | Replay |
| Agenus (NASDAQ:AGEN) Q4 2020 Earnings Call | Mon, Mar 15, 2021 · 8:30 AM ET | Replay |
| Agenus (NASDAQ:AGEN) Q3 2020 Earnings Call | Thu, Oct 29, 2020 · 8:30 AM ET | Replay |
| Agenus (NASDAQ:AGEN) Q2 2020 Earnings Call | Thu, Aug 06, 2020 · 8:30 AM ET | Replay |
| Agenus (NASDAQ:AGEN) Q1 2020 Earnings Call | Thu, May 07, 2020 · 8:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +11.0% |
| Q2 2026 | Aug 7, 2026 | −6.5% |
| Q1 2026 | May 11, 2026 · After close | +5.5% |
| Q4 2025 | Mar 16, 2026 | +28.7% |
| Q3 2025 | Nov 10, 2025 · After close | +1.4% |
| Q2 2025 | Aug 11, 2025 · After close | +12.7% |
| Q1 2025 | May 12, 2025 · After close | −3.4% |
| Q4 2024 | Mar 12, 2025 · Before open | −9.0% |
| Q3 2024 | Nov 12, 2024 · Before open | −20.4% |
| Q2 2024 | Aug 8, 2024 · Before open | +3.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · Before open | −7.3% |
| Q4 2023 | Mar 14, 2024 · Before open | −8.9% |
| Q3 2023 | Nov 7, 2023 · Before open | +4.9% |
| Q2 2023 | Aug 8, 2023 · Before open | −8.1% |
| Q1 2023 | May 9, 2023 · Before open | −5.7% |
| Q4 2022 | Mar 14, 2023 · Before open | +4.7% |
| Q3 2022 | Nov 8, 2022 · Before open | −6.7% |
| Q2 2022 | Aug 9, 2022 · Before open | −1.9% |
| Q1 2022 | May 10, 2022 · Before open | +9.2% |
| Q4 2021 | Mar 1, 2022 · Before open | −4.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 33 slides | November 2026 |
| Investor Presentation (October 2026) | Investor deck | 33 slides | October 2026 |
| Corporate Update (July 2026) | Corporate update | 31 slides | Jul 13, 2026 |
| Investor Presentation (April 2026) | Investor deck | 24 slides | April 2026 |
| Agenus Corporate Event at ESMO 2023 | Conference | 34 slides | Oct 22, 2023 |
| Technical Presentation (June 2023) | Technical | 17 slides | June 2023 |
| 2023 ASCO Gastrointestinal Cancers Symposium | Conference | 10 slides | Jan 21, 2023 |
| 2023 ASCO Gastrointestinal Cancers Symposium | Conference | 10 slides | Jan 21, 2023 |
| Technical Presentation (November 2022) | Technical | 18 slides | Nov 15, 2022 |
| SITC 37th Annual Meeting 2022 | Conference | 18 slides | Nov 12, 2022 |
All 34 decks
Financings
| Raise | Date |
|---|---|
| Private placement of common stock or pre-funded warrants with Series A and Series B purchase warrants Announced: US$85M–US$340M · an accompanying Series A purchase warrant and Series B purchase warrant that, if fully… Buyers: Commodore Capital; RA Capital Management; TCGX; Invus; Ligand Pharmaceuticals Use of proceeds: Advance BOT+BAL in neoadjuvant MSS colon cancer, including the registrational Phase 3 ROBBIN trial | Jul 13, 2026 |
| Strategic investment of common stock Closed: US$16M raised · US$7.5 a share · Porrima Ltd +1 Dealers: Porrima Ltd, Biotech Value Advisors (BVA) Buyers: Zydus ($16 million of Agenus common stock (~2.1 million shares at $7.50 per share)) | Jan 15, 2026 |
| Strategic investment of common stock Announced: about US$16M · US$7.5 a share Buyers: Zydus (approximately 2.1 million shares of common stock at $7.50 per share, approximately $16 million) Use of proceeds: Working capital and general corporate purposes, and to accelerate clinical development, registration and potential commercialization of BOT/BAL | Jun 3, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 114.2M | 103.5M | 156.3M | 98.0M | 295.7M | 88.2M | 150.0M | 36.8M | 42.9M | 22.6M |
| Cost of revenue | 1.02M | 486.0K | 3.11M | 10.6M | 3.47M | 2.35M | 168.3M | 124.6M | 116.1M | 95.0M |
| Gross profit | 33.8M | -52.6M | -81.4M | -99.2M | 113.6M | -56.8M | -18.3M | -87.8M | -73.2M | -72.4M |
| Research and development | 79.3M | 155.5M | 234.6M | 186.7M | 178.6M | 142.6M | 168.3M | 124.6M | 116.1M | 95.0M |
| Selling, general and administrative | 54.4M | 71.9M | 78.7M | 81.0M | 76.4M | 59.2M | 46.0M | 37.3M | 33.7M | 33.1M |
| Operating income | -20.2M | -120.5M | -159.5M | -179.4M | 25.7M | -117.2M | -70.1M | -123.8M | -103.8M | -107.5M |
| Depreciation and amortization | 10.00M | 13.3M | 13.6M | 6.95M | 6.79M | 7.18M | 6.66M | 6.29M | 6.01M | 4.95M |
| EBITDA | -10.2M | -107.1M | -146.0M | -172.5M | 32.5M | -110.1M | -63.5M | -117.5M | -97.8M | -102.5M |
| Interest expense | 55.6M | 120.4M | 103.9M | 64.1M | 65.7M | 61.1M | 41.5M | 25.3M | 31.3M | 19.4M |
| Income before tax | -3.08M | -232.3M | -257.4M | -230.7M | -28.7M | -182.9M | -111.6M | -162.0M | -120.7M | -127.0M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -101.0K | -227.4M | -246.0M | -220.3M | -24.1M | -181.1M | -107.9M | -159.9M | -120.7M | -127.0M |
| Earnings per share, basic | 0.00 | -10.59 | -13.75 | -15.64 | -0.11 | -1.05 | -0.80 | -1.44 | -1.23 | -1.46 |
| Earnings per share, diluted | 0.00 | -10.59 | -13.75 | -15.64 | -0.11 | -1.05 | -0.80 | -1.44 | -1.23 | -1.46 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.00M | 40.4M | 76.1M | 178.7M | 291.9M | 99.9M | 61.8M | 53.1M | 60.2M | 71.4M |
| Short-term investments | 0 | 447.0K | 14.7M | 15.0M | 0 | 0 | 0 | 4.99M | ||
| Receivables | 1.83M | 407.0K | 25.8M | 2.74M | 1.52M | 1.16M | 16.3M | 938.0K | 1.13M | 11.4M |
| Inventory | 1 | 13.8M | 20.4M | 10.7M | 0 | 55.0K | 79.5K | 88.2K | ||
| Current assets | 133.4M | 45.6M | 112.4M | 213.1M | 332.0M | 113.8M | 86.5M | 74.8M | 73.6M | 91.3M |
| Property, plant and equipment | 15.5M | 120.1M | 133.4M | 133.0M | 60.0M | 26.8M | 26.3M | 25.1M | 26.2M | 25.6M |
| Goodwill | 24.1M | 24.1M | 24.7M | 25.5M | 24.9M | 25.5M | 23.2M | 22.9M | 23.0M | 22.4M |
| Total assets | 226.8M | 226.3M | 313.9M | 413.6M | 466.0M | 214.5M | 155.3M | 136.4M | 138.4M | 157.0M |
| Accounts payable | 83.0M | 61.5M | 61.4M | 40.9M | 30.5M | 17.0M | 13.6M | 13.6M | 8.09M | 5.43M |
| Current liabilities | 323.5M | 221.4M | 255.9M | 189.0M | 156.9M | 129.9M | 122.2M | 68.1M | 56.4M | 40.9M |
| Long-term debt | 0 | 30.5M | 12.8M | 12.6M | 12.8M | 18.9M | 13.4M | 13.2M | 142.4M | 130.5M |
| Total debt | 89.3M | 33.2M | 12.9M | 13.2M | 13.6M | 19.7M | 14.0M | 13.4M | 163.0M | 130.7M |
| Total liabilities | 504.7M | 532.7M | 462.3M | 468.5M | 418.0M | 426.0M | 386.7M | 310.9M | 214.2M | 196.1M |
| Shareholders' equity | -271.1M | -326.4M | -160.3M | -61.3M | 34.4M | -203.7M | -225.4M | -172.5M | -75.8M | -39.1M |
| Shares outstanding | 35.3M | 23.6M | 19.7M | 25.3M | 418.9M | 332.5M | 257.2M | 204.7M | 161.6M | 134.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -77.2M | -158.3M | -224.2M | -175.4M | 10.1M | -139.1M | -18.7M | -131.1M | -94.2M | -80.0M |
| Capital spending | -6.00K | -576.0K | -9.95M | -53.1M | -33.8M | -3.47M | -4.66M | -3.60M | -3.12M | -12.5M |
| Free cash flow | -77.2M | -158.9M | -234.2M | -228.4M | -23.7M | -142.6M | -23.3M | -134.7M | -97.3M | -92.5M |
| Cash from investing | 1.19M | 27.0K | 3.40M | -33.6M | -43.1M | -4.44M | -4.66M | -3.59M | 2.06M | 17.6M |
| Cash from financing | 36.6M | 122.8M | 119.9M | 95.8M | 225.3M | 183.9M | 31.3M | 128.3M | 80.5M | -2.46M |
| Dividends paid | -9.13M | 0 | -16.0M | -1.18M | ||||||
| Share buybacks | -87.0K | 0 | -5.17M | -3.79M | -1.65M | 176.4M | 30.0M | 86.0M | -527.0K | -667.0K |
| Change in cash | -39.4M | -35.7M | -101.6M | -113.3M | 192.1M | 40.7M | 8.75M | -7.13M | -11.3M | -65.3M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 15, 2026 | Insider trade | SEC |
| S-3 · Registration statement | Sep 11, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Sep 2, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Aug 18, 2026 | Material contract | SEC |
| 424B3 · Prospectus | Aug 17, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 17, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 12, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 11, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 7, 2026 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | Aug 7, 2026 | Offer document | SEC |
| S-3 · Registration statement | Aug 7, 2026 | Offer document | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | Jul 28, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 27, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 20, 2026 | Big-stake notice | SEC |
| S-3 · Registration statement | Jul 17, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 13, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 6, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 8-K · Current report | May 15, 2026 | Management or board change | SEC |
| DEFA14A · Additional proxy material | May 13, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2026 | Results | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Apr 20, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 26, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 16, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 16, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Jan 23, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jan 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 16, 2026 | Acquisition or disposal | SEC |
| 8-K · Current report | Jan 14, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| S-3ASR · Registration statement | Dec 29, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| 4 · Change in ownership | Nov 5, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 21, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 9, 2025 | Material contract | SEC |
| 4 · Change in ownership | Oct 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 23, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 29, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 26, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 11, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 28, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| DEFR14A | Jun 6, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jun 4, 2025 | Material contract | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jun 2, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 28, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | May 15, 2025 | Other filings | SEC |
| S-3 · Registration statement | May 12, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| 4 · Change in ownership | May 6, 2025 | Insider trade | SEC |
| DEFR14A | May 5, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 30, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 30, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 22, 2025 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Apr 18, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 17, 2025 | Annual report | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 11, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 26, 2025 | Material contract | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 5, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 27, 2024 | Material contract | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 8-K/A · Current report, amended | Nov 8, 2024 | Management or board change | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 5, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Nov 4, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Oct 22, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 424B5 · Prospectus | Aug 8, 2024 | Offer document | SEC |
| 3 · Initial statement of ownership | Aug 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 2, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 25, 2024 | Offer document | SEC |
| 3 · Initial statement of ownership | Jun 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
This page holds 200 of 1,005 filings. Open Filings
Cap table
Built by 6ix from Agenus Inc.’s releases · as of Nov 3, 2026
- Common shares
- 45,246,510
- Fully diluted
- 45,246,510
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 45,246,510 | Nov 3, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 3, 2026 | 45,246,510 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Noubar Afeyan Other companies: Generate Biomedicines, Inc. (Chair of the Board · Since at least Feb 26, 2026); Foghorn Therapeutics Inc. (Director · Since at least Jan 13, 2026); Moderna, Inc. (Director · Since at least Dec 7, 2018); BG Medicine Inc (Director · Since at least Feb 3, 2011); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 7, 2023 · Past); Kaleido Biosciences, Inc. (Director · Feb 27, 2019 – Mar 4, 2019 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – May 12, 2022 · Past); Evelo Biosciences, Inc. (Director · May 8, 2018 – Jun 12, 2019 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 21, 2016 · Past); Seres Therapeutics, Inc. (Director · Jun 25, 2015 – Jun 18, 2019 · Past); Eleven Biotherapeutics Inc (Director · Feb 5, 2014 – Mar 20, 2014 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Sep 25, 2013 · Past); Color Kinetics Inc (Director · Jan 3, 2006 – Aug 24, 2007 · Past) | Director · Jan 13, 2005 – Jun 7, 2007 · Past |
| Shalini Sharp Other companies: Iambic Therapeutics, Inc. (Board Member · Since at least Nov 5, 2026); BeOne Medicines Ltd. Class A (Director · Since at least Jun 11, 2026); Septerna, Inc. (Director · Since at least Oct 24, 2024); Organon & Co. (Director · Since at least May 14, 2021); Neurocrine Biosciences, Inc. (Director · Since at least Feb 1, 2020); Nuvation Bio Inc. (Director · Jun 30, 2020 – Feb 10, 2021 · Past); Precision BioSciences, Inc. (Director · Mar 27, 2019 – May 10, 2021 · Past); Sutro Biopharma, Inc. (Director · Nov 8, 2018 – Jun 6, 2022 · Past); Ultragenyx Pharmaceutical Inc. (EVP, Finance · Jan 30, 2014 – Oct 14, 2020 · Past) | Director · Oct 1, 2006 – Mar 2, 2018 · Past |
| Thomas Harrison Other companies: Acurx Pharmaceuticals, Inc. (Director · Since at least Jun 24, 2021); Advanced Flower Capital Inc. (Director · Since at least Mar 18, 2021); Zynerba Pharmaceuticals Inc (Director · Aug 4, 2015 – Jun 6, 2018 · Past); Fifth Street Asset Management Inc (Director · Oct 29, 2014 – Dec 8, 2017 · Past); PLx Pharma Inc (Director · Mar 12, 2014 – Jan 17, 2017 · Past); rVue Holdings Inc (Director · Sep 19, 2013 – Dec 3, 2013 · Past); Epocrates Inc (Director · Feb 1, 2011 – Mar 12, 2013 · Past); Omnicom Group Inc. (Chrmn/CEO Divers. Agency Serv. · May 4, 2006 – Mar 31, 2010 · Past); Morgans Hotel Group Company (Director · Feb 13, 2006 – May 17, 2012 · Past) | Director · Since at least Aug 7, 2024 |
| Paul N Clark Other companies: Keysight Technologies Inc. (Director · Oct 6, 2014 – Mar 19, 2021 · Past); Talecris Biotherapeutics Holdings Corp (Director · Sep 30, 2009 – Jun 1, 2011 · Past); Amylin Pharmaceuticals LLC (Director · Jun 9, 2009 – Apr 9, 2012 · Past); Agilent Technologies, Inc. (Director · May 17, 2006 – Mar 18, 2021 · Past); Icos Corp (Chairman, CEO & President, Director · Jan 24, 2006 – Jan 29, 2007 · Past) | Director · Aug 27, 2020 – Apr 1, 2021 · Past |
| John N. Hatsopoulos Other companies: Tecogen Inc. (Lead Director · Since at least Oct 1, 2013); EuroSite Power Inc (Director · Jul 25, 2012 – May 12, 2016 · Past); American DG Energy Inc (Co-Chief Executive Officer, Director · Mar 19, 2008 – May 23, 2017 · Past); American Caresource Holdings Inc (Director · Dec 31, 2007 – Jul 20, 2010 · Past) | Director · Jun 7, 2007 – Dec 8, 2011 · Past |
| Shahzad Malik Other companies: Acutus Medical Inc. (Director · Aug 5, 2020 – Jun 17, 2021 · Past); Axonics Modulation Technologies Inc (Director · Oct 30, 2018 – Dec 6, 2018 · Past); Histogen Inc (Director · Jun 23, 2016 – Jun 23, 2016 · Past); Aravive Inc (Director · Jun 29, 2015 – Sep 12, 2019 · Past) | Director · Jun 15, 2016 – Jun 15, 2016 · Past |
| Charles Evan Ballantyne Other companies: Gain Therapeutics, Inc. (Chief Financial Officer · Apr 10, 2023 – Apr 10, 2023 · Past); Theriva Biologics, Inc. (Chief Financial Officer · Feb 6, 2012 – Jan 8, 2015 · Past); Clinical Data Inc (EVP, CFO · Jun 14, 2007 – Apr 12, 2011 · Past) | CFO · Jun 17, 2015 – Jun 14, 2016 · Past |
| Garo H. Armen Other companies: Protagenic Therapeutics, Inc. (EXEC. CHAIR & PRINCIPAL OFF, Director · Since at least Feb 12, 2016); MiNK Therapeutics, Inc. (Director · Oct 13, 2021 – May 5, 2023 · Past); Color Kinetics Inc (Director · May 24, 2006 – Aug 24, 2007 · Past) | Chairman and Chief Executive Officer · Since at least Feb 22, 2006 |
| Hyam Levitsky Other companies: Century Therapeutics, Inc. (President of R&D · Jun 17, 2021 – Mar 7, 2024 · Past); Replimune Group, Inc. (Director · Jul 19, 2018 – Apr 1, 2024 · Past); Juno Therapeutics Inc (EVP, Research & CSO · May 27, 2015 – Feb 7, 2017 · Past) | Director · Sep 13, 2006 – Aug 28, 2011 · Past |
| Mark Kessel Other companies: VivoSim Labs, Inc. (Director · Aug 17, 2016 – Sep 5, 2019 · Past); Dynavax Technologies Corporation (Director · Dec 30, 2009 – Oct 16, 2012 · Past); Oncotelic Therapeutics Inc (Director · Oct 22, 2008 – Oct 31, 2011 · Past) | Director · Jan 13, 2006 – Oct 2, 2006 · Past |
All 40 people
| Person | Seat |
|---|---|
| Timothy R. Wright Other companies: Protagenic Therapeutics, Inc. (Director · Mar 25, 2024 – Mar 25, 2024 · Past); MiMedx Group, Inc (Chief Executive Officer, Director · May 13, 2019 – Jun 9, 2022 · Past); Covidien plc (Senior Vice President · Jun 29, 2007 – Dec 1, 2010 · Past) | Lead Director · Since at least Dec 7, 2006 |
| Brian Corvese Other companies: MiNK Therapeutics, Inc. (Director · Since at least Oct 13, 2021); Protagenic Therapeutics, Inc. (Director · Mar 25, 2024 – Mar 25, 2024 · Past) | Director · Since at least Dec 17, 2020 |
| Christine M Klaskin Other companies: MiNK Therapeutics, Inc. (Treasurer · Oct 13, 2021 – Oct 13, 2021 · Past); American DG Energy Inc (Director · Jan 18, 2012 – May 23, 2017 · Past) | PFO & PAO · Since at least Feb 12, 2008 |
| Jennifer Buell Other companies: MiNK Therapeutics, Inc. (President and CEO · Since at least Oct 13, 2021); Protagenic Therapeutics, Inc. (Director · Jul 18, 2020 – Mar 25, 2024 · Past) | President and CEO of MiNK Therapeutics and Chairman, Executive Council at Agenus · Since at least Jun 29, 2017 |
| Kerry Wentworth Other companies: Nuvation Bio Inc. (Chief Regulatory Officer · Since at least May 23, 2022); Flexion Therapeutics Inc (Chief Regulatory Officer · Dec 21, 2017 – Nov 19, 2021 · Past) | VP, Clinical, Reg & Qual · Jul 20, 2006 – Feb 26, 2014 · Past |
| Renu Gupta Other companies: Corbus Pharmaceuticals Holdings, Inc. (Director · Nov 24, 2014 – May 25, 2017 · Past); Insmed Incorporated (Executive Vice President & CMO · Dec 1, 2010 – Jan 31, 2014 · Past) | Sr. VP Development · Feb 24, 2006 – Jul 20, 2006 · Past |
| Austin Charette Other companies: MiNK Therapeutics, Inc. (Principal Accounting Officer · Since at least Mar 13, 2026) | Principal Accounting Officer · Since at least Jan 8, 2026 |
| Bruce Leicher Other companies: Momenta Pharmaceuticals Inc (SVP & General Counsel · Jul 24, 2008 – Aug 21, 2018 · Past) | VP, General Counsel · Sep 15, 2006 – Dec 15, 2006 · Past |
| Christian Cortis Other companies: Tectonic Therapeutic, Inc. (Chief Operating Officer · Jun 20, 2024 – Jun 20, 2024 · Past) | Chief Strategy Officer · Jun 19, 2019 – Jul 23, 2019 · Past |
| Frank V Atlee III Other companies: Monsanto (Director · Jan 27, 2006 – Dec 20, 2010 · Past) | Director · Jan 13, 2006 – Jun 7, 2007 · Past |
| Susan Hirsch Other companies: Tecogen Inc. (Director · Since at least Sep 22, 2023) | Managing Director at Nuveen · Since at least Oct 8, 2020 |
| Ulf Wiinberg Other companies: MiNK Therapeutics, Inc. (Director · Since at least Oct 13, 2021) | Director · May 17, 2016 – Oct 1, 2024 · Past |
| Adam Krauss | Chief Legal Officer · Dec 17, 2020 – Jun 15, 2021 · Past |
| Alex Duncan | Chief Technology Officer · Jun 19, 2019 – Jul 23, 2019 · Past |
| Allison M Jeynes-Ellis | Director · Nov 7, 2018 – Feb 5, 2024 · Past |
| Craig Winter | Chief Information Officer · Since at least Nov 4, 2026 |
| Gamil De Chadarevian | Director · Feb 28, 2006 – Feb 28, 2006 · Past |
| José Iglesias | Chief Medical Affairs Officer · Since at least Nov 18, 2025 |
| Marco Tullio Marcucci | Director · Since at least Aug 5, 2026 |
| Ozer Baysal | Chief Commercial Officer · Apr 26, 2016 – Jun 20, 2018 · Past |
| Pramod Srivastava | Director · Feb 23, 2006 – Jun 7, 2007 · Past |
| Robin Taylor | Chief Commercial Officer · Since at least Nov 2, 2026 |
| Roman Chicz | Sr. VP, Research & Development · Feb 24, 2006 – May 18, 2007 · Past |
| Steven J O'Day | Chief Medical Officer · Since at least Feb 10, 2021 |
| Steven O’Day | Chief Medical Officer · Since at least Nov 2, 2026 |
| Tom Dechaene | Director · Jun 7, 2007 – Jan 4, 2016 · Past |
| Tom Harrison | Director · Since at least Oct 2, 2026 |
| Tracy Mazza Clemente | Chief People Officer · Since at least Nov 4, 2026 |
| Wadih Jordan | Director · Apr 1, 2010 – Oct 3, 2022 · Past |
| Zack Armen | VP, Corporate Development & Investor Relations · Since at least Nov 2, 2026 |
Log in to ask 6ix AI your own questions about Agenus Inc.